PubRank

Jesús Avila

Author PubWeight™ 135.11‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem 2003 2.65
2 Inhibition of glycogen synthase kinase 3beta during heart failure is protective. Circ Res 2007 2.22
3 Glycogen synthase kinase 3: a drug target for CNS therapies. J Neurochem 2004 1.97
4 Neuronal induction of the immunoproteasome in Huntington's disease. J Neurosci 2003 1.83
5 Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. Eur J Neurosci 2007 1.50
6 Extracellular tau is toxic to neuronal cells. FEBS Lett 2006 1.47
7 Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. J Neurosci 2006 1.44
8 Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments. J Neurochem 2002 1.42
9 Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J Neurochem 2006 1.34
10 Is oxidative damage the fundamental pathogenic mechanism of Alzheimer's and other neurodegenerative diseases? Free Radic Biol Med 2002 1.34
11 GSK3: a possible link between beta amyloid peptide and tau protein. Exp Neurol 2009 1.32
12 Early changes in hippocampal Eph receptors precede the onset of memory decline in mouse models of Alzheimer's disease. J Alzheimers Dis 2009 1.29
13 Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J Alzheimers Dis 2003 1.29
14 Lymphocyte chemotaxis is regulated by histone deacetylase 6, independently of its deacetylase activity. Mol Biol Cell 2006 1.29
15 Glycogen synthase kinase-3 plays a crucial role in tau exon 10 splicing and intranuclear distribution of SC35. Implications for Alzheimer's disease. J Biol Chem 2003 1.19
16 Proteostasis of tau. Tau overexpression results in its secretion via membrane vesicles. FEBS Lett 2011 1.17
17 Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models. Neurobiol Dis 2005 1.16
18 Tissue-nonspecific alkaline phosphatase promotes the neurotoxicity effect of extracellular tau. J Biol Chem 2010 1.15
19 N-terminal cleavage of GSK-3 by calpain: a new form of GSK-3 regulation. J Biol Chem 2007 1.15
20 A role of MAP1B in Reelin-dependent neuronal migration. Cereb Cortex 2004 1.13
21 Accelerated amyloid deposition, neurofibrillary degeneration and neuronal loss in double mutant APP/tau transgenic mice. Neurobiol Dis 2005 1.11
22 Prion peptide induces neuronal cell death through a pathway involving glycogen synthase kinase 3. Biochem J 2003 1.11
23 Regulation of GSK3 isoforms by phosphatases PP1 and PP2A. Mol Cell Biochem 2010 1.08
24 Tau-knockout mice show reduced GSK3-induced hippocampal degeneration and learning deficits. Neurobiol Dis 2009 1.06
25 Cooexpression of FTDP-17 tau and GSK-3beta in transgenic mice induce tau polymerization and neurodegeneration. Neurobiol Aging 2005 1.05
26 Cleavage and conformational changes of tau protein follow phosphorylation during Alzheimer's disease. Int J Exp Pathol 2008 1.04
27 Biochemical, ultrastructural, and reversibility studies on huntingtin filaments isolated from mouse and human brain. J Neurosci 2004 1.04
28 Neuronal apoptosis and reversible motor deficit in dominant-negative GSK-3 conditional transgenic mice. EMBO J 2007 1.04
29 Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease. Curr Pharm Des 2010 1.04
30 MAP1B is required for Netrin 1 signaling in neuronal migration and axonal guidance. Curr Biol 2004 1.04
31 A new mutation of the tau gene, G303V, in early-onset familial progressive supranuclear palsy. Arch Neurol 2005 1.04
32 Glycogen synthase kinase-3 is activated in neuronal cells by Galpha12 and Galpha13 by Rho-independent and Rho-dependent mechanisms. J Neurosci 2002 1.03
33 Creating a transatlantic research enterprise for preventing Alzheimer's disease. Alzheimers Dement 2009 1.02
34 Chronological primacy of oxidative stress in Alzheimer disease. Neurobiol Aging 2005 1.02
35 The role of GSK3 in Alzheimer disease. Brain Res Bull 2009 1.00
36 MAP1B regulates microtubule dynamics by sequestering EB1/3 in the cytosol of developing neuronal cells. EMBO J 2013 1.00
37 Deconstructing mitochondrial dysfunction in Alzheimer disease. Oxid Med Cell Longev 2013 0.99
38 The influence of phospho-τ on dendritic spines of cortical pyramidal neurons in patients with Alzheimer's disease. Brain 2013 0.99
39 GSK3β overexpression induces neuronal death and a depletion of the neurogenic niches in the dentate gyrus. Hippocampus 2010 0.99
40 Estradiol prevents neural tau hyperphosphorylation characteristic of Alzheimer's disease. Ann N Y Acad Sci 2005 0.99
41 GSK3 inhibitors and disease. Mini Rev Med Chem 2009 0.98
42 Alpha-helix structure in Alzheimer's disease aggregates of tau-protein. Biochemistry 2002 0.98
43 The role of glycogen synthase kinase 3 in the early stages of Alzheimers' disease. FEBS Lett 2008 0.98
44 Regulation of tau phosphorylation and protection against beta-amyloid-induced neurodegeneration by lithium. Possible implications for Alzheimer's disease. Bipolar Disord 2002 0.98
45 Role of MAP1B in axonal retrograde transport of mitochondria. Biochem J 2006 0.97
46 Revisiting the Role of Acetylcholinesterase in Alzheimer's Disease: Cross-Talk with P-tau and β-Amyloid. Front Mol Neurosci 2011 0.97
47 Formation of aberrant phosphotau fibrillar polymers in neural cultured cells. Eur J Biochem 2002 0.96
48 Microtubule-associated protein 1B (MAP1B) is required for dendritic spine development and synaptic maturation. J Biol Chem 2011 0.95
49 Effect of the lipid peroxidation product acrolein on tau phosphorylation in neural cells. J Neurosci Res 2003 0.95
50 Neurotoxicity induced by okadaic acid in the human neuroblastoma SH-SY5Y line can be differentially prevented by α7 and β2* nicotinic stimulation. Toxicol Sci 2011 0.94
51 Tau overexpression results in its secretion via membrane vesicles. Neurodegener Dis 2012 0.94
52 Glycosaminoglycans and beta-amyloid, prion and tau peptides in neurodegenerative diseases. Peptides 2002 0.94
53 Glycogen Synthase Kinase-3 Modulates Neurite Outgrowth in Cultured Neurons: Possible Implications for Neurite Pathology in Alzheimer's Disease. J Alzheimers Dis 1999 0.92
54 Three-dimensional structure of human tubulin chaperone cofactor A. J Mol Biol 2002 0.92
55 GSK-3 dependent phosphoepitopes recognized by PHF-1 and AT-8 antibodies are present in different tau isoforms. Neurobiol Aging 2003 0.91
56 Effect of quinones on microtubule polymerization: a link between oxidative stress and cytoskeletal alterations in Alzheimer's disease. Biochim Biophys Acta 2004 0.91
57 Characteristics of the binding of thioflavin S to tau paired helical filaments. J Alzheimers Dis 2006 0.90
58 Role of neuroinflammation in adult neurogenesis and Alzheimer disease: therapeutic approaches. Mediators Inflamm 2013 0.90
59 Microtubule-associated protein 1B interaction with tubulin tyrosine ligase contributes to the control of microtubule tyrosination. Dev Neurosci 2008 0.89
60 Expression of the ghrelin and neurotensin systems is altered in the temporal lobe of Alzheimer's disease patients. J Alzheimers Dis 2010 0.89
61 Binding of microtubule-associated protein 1B to LIS1 affects the interaction between dynein and LIS1. Biochem J 2005 0.89
62 Alzheimer disease: caspases first. Nat Rev Neurol 2010 0.89
63 Tangling with hypothermia. Nat Med 2004 0.88
64 GSK-3 Mouse Models to Study Neuronal Apoptosis and Neurodegeneration. Front Mol Neurosci 2011 0.88
65 Enhanced induction of the immunoproteasome by interferon gamma in neurons expressing mutant Huntingtin. Neurotox Res 2004 0.88
66 Tau aggregates and tau pathology. J Alzheimers Dis 2008 0.88
67 End binding protein-1 (EB1) complements microtubule-associated protein-1B during axonogenesis. J Neurosci Res 2005 0.87
68 Binding of Hsp90 to tau promotes a conformational change and aggregation of tau protein. J Alzheimers Dis 2009 0.87
69 Neuronal microtubule-associated protein 2D is a dual a-kinase anchoring protein expressed in rat ovarian granulosa cells. J Biol Chem 2004 0.87
70 M1 muscarinic receptor activation protects neurons from beta-amyloid toxicity. A role for Wnt signaling pathway. Neurobiol Dis 2004 0.87
71 Tau regulates the localization and function of End-binding proteins 1 and 3 in developing neuronal cells. J Neurochem 2015 0.86
72 The anti-inflammatory and cholinesterase inhibitor bifunctional compound IBU-PO protects from beta-amyloid neurotoxicity by acting on Wnt signaling components. Neurobiol Dis 2005 0.86
73 Tramiprosate, a drug of potential interest for the treatment of Alzheimer's disease, promotes an abnormal aggregation of tau. Mol Neurodegener 2007 0.86
74 Further understanding of tau phosphorylation: implications for therapy. Expert Rev Neurother 2015 0.86
75 Taurine, an inducer for tau polymerization and a weak inhibitor for amyloid-beta-peptide aggregation. Neurosci Lett 2007 0.86
76 Nuclear localization of N-terminal mutant huntingtin is cell cycle dependent. Eur J Neurosci 2002 0.86
77 Zeta 14-3-3 protein favours the formation of human tau fibrillar polymers. Neurosci Lett 2004 0.85
78 Function of tau protein in adult newborn neurons. FEBS Lett 2009 0.85
79 Tau deficiency leads to the upregulation of BAF-57, a protein involved in neuron-specific gene repression. FEBS Lett 2010 0.85
80 P24, a glycogen synthase kinase 3 (GSK 3) inhibitor. Biochim Biophys Acta 2002 0.85
81 Quinones facilitate the self-assembly of the phosphorylated tubulin binding region of tau into fibrillar polymers. Biochemistry 2004 0.84
82 Expression of Somatostatin, cortistatin, and their receptors, as well as dopamine receptors, but not of neprilysin, are reduced in the temporal lobe of Alzheimer's disease patients. J Alzheimers Dis 2010 0.84
83 Dual effects of increased glycogen synthase kinase-3β activity on adult neurogenesis. Hum Mol Genet 2012 0.84
84 The involvement of cholinergic neurons in the spreading of tau pathology. Front Neurol 2013 0.84
85 Progressive supranuclear palsy and tau hyperphosphorylation in a patient with a C212Y parkin mutation. J Alzheimers Dis 2002 0.83
86 Tau isoform with three microtubule binding domains is a marker of new axons generated from the subgranular zone in the hippocampal dentate gyrus: implications for Alzheimer's disease. J Alzheimers Dis 2012 0.83
87 Tau protein and adult hippocampal neurogenesis. Front Neurosci 2012 0.83
88 Heme catabolism and heme oxygenase in neurodegenerative disease. Antioxid Redox Signal 2004 0.82
89 Memantine inhibits calpain-mediated truncation of GSK-3 induced by NMDA: implications in Alzheimer's disease. J Alzheimers Dis 2009 0.82
90 Altered Ca2+ dependence of synaptosomal plasma membrane Ca2+-ATPase in human brain affected by Alzheimer's disease. FASEB J 2009 0.82
91 Tau regulates the subcellular localization of calmodulin. Biochem Biophys Res Commun 2011 0.82
92 Patient-derived olfactory mucosa cells but not lung or skin fibroblasts mediate axonal regeneration of retinal ganglion neurons. Neurosci Lett 2011 0.81
93 Calpain-mediated truncation of GSK-3 in post-mortem brain samples. J Neurosci Res 2009 0.81
94 Expression of an altered form of tau in Sf9 insect cells results in the assembly of polymers resembling Alzheimer's paired helical filaments. Brain Res 2004 0.81
95 Selenomethionine incorporation into amyloid sequences regulates fibrillogenesis and toxicity. PLoS One 2011 0.81
96 Alterations in the nuclear architecture produced by the overexpression of tau protein in neuroblastoma cells. J Alzheimers Dis 2013 0.81
97 Altered expression of brain acetylcholinesterase in FTDP-17 human tau transgenic mice. Neurobiol Aging 2011 0.81
98 MDMA impairs mitochondrial neuronal trafficking in a Tau- and Mitofusin2/Drp1-dependent manner. Arch Toxicol 2014 0.81
99 Acetylcholine receptors and tau phosphorylation. Curr Mol Med 2006 0.81
100 Olfactory Ensheathing Glia: Drivers of Axonal Regeneration in the Central Nervous System? J Biomed Biotechnol 2002 0.80
101 Alzheimer's disease as an inflammatory disease. Biomol Concepts 2017 0.80
102 The role of the VQIVYK peptide in tau protein phosphorylation. J Neurochem 2007 0.80
103 Hyperexcitability and epileptic seizures in a model of frontotemporal dementia. Neurobiol Dis 2013 0.80
104 Common mechanisms in neurodegeneration. Nat Med 2010 0.80
105 Immortalized olfactory ensheathing glia promote axonal regeneration of rat retinal ganglion neurons. J Neurochem 2003 0.80
106 GSK3β is involved in the relief of mitochondria pausing in a Tau-dependent manner. PLoS One 2011 0.80
107 New insights into the role of glycogen synthase kinase-3 in Alzheimer's disease. Expert Opin Ther Targets 2013 0.80
108 Characterization by atomic force microscopy and cryoelectron microscopy of tau polymers assembled in Alzheimer's disease. J Alzheimers Dis 2001 0.80
109 Prevention of senescence progression in reversibly immortalized human ensheathing glia permits their survival after deimmortalization. Mol Ther 2009 0.80
110 Phosphorylation modulates the alpha-helical structure and polymerization of a peptide from the third tau microtubule-binding repeat. Biochim Biophys Acta 2004 0.80
111 Ephrin-B1 promotes dendrite outgrowth on cerebellar granule neurons. Mol Cell Neurosci 2002 0.80
112 Coenzyme q induces tau aggregation, tau filaments, and Hirano bodies. J Neuropathol Exp Neurol 2008 0.79
113 Microtubule-associated protein 1b, a neuronal marker involved in odontoblast differentiation. J Endod 2009 0.79
114 The quest to repair the damaged spinal cord. Recent Pat CNS Drug Discov 2006 0.79
115 Changes in tau phosphorylation in hibernating rodents. J Neurosci Res 2013 0.79
116 Tau phosphorylation and assembly. Acta Neurobiol Exp (Wars) 2004 0.79
117 Tau as a molecular marker of development, aging and neurodegenerative disorders. Curr Aging Sci 2008 0.79
118 Inhibition of GSK3 dependent tau phosphorylation by metals. Curr Alzheimer Res 2006 0.79
119 Cortistatin as a therapeutic target in inflammation. Expert Opin Ther Targets 2007 0.79
120 Sodium tungstate decreases the phosphorylation of tau through GSK3 inactivation. J Neurosci Res 2006 0.79
121 Understanding the relationship between GSK-3 and Alzheimer's disease: a focus on how GSK-3 can modulate synaptic plasticity processes. Expert Rev Neurother 2013 0.78
122 Phosphorylated tau in neuritic plaques of APP(sw)/Tau (vlw) transgenic mice and Alzheimer disease. Acta Neuropathol 2008 0.78
123 Testing the ubiquitin-proteasome hypothesis of neurodegeneration in vivo. Trends Neurosci 2004 0.78
124 Neurotoxic dopamine quinone facilitates the assembly of tau into fibrillar polymers. Mol Cell Biochem 2005 0.78
125 Inhibition by Aplidine of the aggregation of the prion peptide PrP 106-126 into beta-sheet fibrils. Biochim Biophys Acta 2003 0.78
126 A clonal cell line from immortalized olfactory ensheathing glia promotes functional recovery in the injured spinal cord. Mol Ther 2006 0.78
127 Expression of plasminogen activator inhibitor-1 by olfactory ensheathing glia promotes axonal regeneration. Glia 2011 0.78
128 Epigenetic control of somatostatin and cortistatin expression by β amyloid peptide. J Neurosci Res 2011 0.78
129 In vitro tau fibrillization: mapping protein regions. Biochim Biophys Acta 2006 0.78
130 Reversibly immortalized human olfactory ensheathing glia from an elderly donor maintain neuroregenerative capacity. Glia 2010 0.78
131 Preface. Alzheimer's disease: advances for a new century. J Alzheimers Dis 2013 0.77
132 Comparative biology and pathology of oxidative stress in Alzheimer and other neurodegenerative diseases: beyond damage and response. Comp Biochem Physiol C Toxicol Pharmacol 2002 0.77
133 Alzheimer Center Reina Sofia Foundation: fighting the disease and providing overall solutions. J Alzheimers Dis 2010 0.77
134 Calpain regulates N-terminal interaction of GSK-3β with 14-3-3ζ, p53 and PKB but not with axin. Neurochem Int 2011 0.77
135 A two-hybrid screening of human Tau protein: interactions with Alu-derived domain. Neuroreport 2002 0.77
136 High level of amyloid precursor protein expression in neurite-promoting olfactory ensheathing glia (OEG) and OEG-derived cell lines. J Neurosci Res 2003 0.76
137 Binding of tau protein to the ends of ex vivo paired helical filaments. J Alzheimers Dis 2008 0.76
138 A neuroregenerative human ensheathing glia cell line with conditional rapid growth. Cell Transplant 2010 0.76
139 Retracted gamma-cleavage-independent functions of presenilin, nicastrin, and Aph-1 regulate cell-junction organization and prevent tau toxicity in vivo. Neuron 2006 0.76
140 Effect of acetylcholine on tau phosphorylation in human neuroblastoma cells. J Mol Neurosci 2006 0.76
141 Is tau a suitable therapeutical target in tauopathies? World J Biol Chem 2010 0.76
142 Tau modifiers as therapeutic targets for Alzheimer's disease. Biochim Biophys Acta 2005 0.76
143 Effect of cortistatin on tau phosphorylation at Ser262 site. J Neurosci Res 2008 0.75
144 Use of okadaic acid to identify relevant phosphoepitopes in pathology: a focus on neurodegeneration. Mar Drugs 2013 0.75
145 Microtubule depolymerization and tau phosphorylation. J Alzheimers Dis 2013 0.75
146 A meeting to remember: meeting on memory and related disorders. EMBO Rep 2006 0.75
147 Role of polyglycine repeats in the regulation of glycogen synthase kinase activity. Protein Pept Lett 2008 0.75
148 TNAP Plays a Key Role in Neural Differentiation as well as in Neurodegenerative Disorders. Subcell Biochem 2015 0.75
149 Transgenic mouse models with tau pathology to test therapeutic agents for Alzheimer's disease. Mini Rev Med Chem 2002 0.75
150 Sulfo-glycosaminoglycan content affects PHF-tau solubility and allows the identification of different types of PHFs. Brain Res 2002 0.75
151 A mouse model to study tau pathology related with tau phosphorylation and assembly. J Neurol Sci 2007 0.75
152 Characterization of Alzheimer paired helical filaments by electron microscopy. Microsc Res Tech 2005 0.75
153 Protocols for Monitoring the Development of Tau Pathology in Alzheimer's Disease. Methods Mol Biol 2016 0.75
154 Modifications of tau protein during neuronal cell death. J Alzheimers Dis 2001 0.75